Drug Channels

JUNE 12, 2024

The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J. Fein, Ph.D.,

Pharmacy 52

Pharmacy Specialty Pharmacies Hospitals Marketing 52

Drug Channels

MAY 23, 2023

In 2022, the PBM market remained highly consolidated—although there were some intriguing share shifts among the largest players. Below, you’ll find Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share based on equivalent prescription claims. d/b/a Drug Channels Institute.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

OCTOBER 8, 2021

Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Specialty Pharmacies 98

Specialty Pharmacies Marketing Pharmacy Drugs 98

Drug Channels

JUNE 18, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. One important update to the figures below: We (and many others) had significantly underestimated Walgreens' revenues and market share. All rights reserved.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Marketing Hospitals 52

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. d/b/a Drug Channels Institute. to 1:30 p.m.

Marketing 97

Marketing Biosimilars Drugs Hospitals 97

Drug Channels

JUNE 17, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Read on for Drug Channels Institute’s (DCI’s) latest market share figures, along with a preview of the industry changes that will shift these shares over the next few years.

Pharmacy 52

Pharmacy Marketing Drugs 52

Drug Channels

JANUARY 28, 2022

It's a moderated discussion with payers on how the changing market might impact their management strategies in immunology. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 98

Biosimilars Marketing Drugs 98

Drug Channels

APRIL 18, 2023

Last Friday was the last day to submit comments on CMS's initial guidance on the drug price negotiation program. The IRA will alter many crucial aspects of the Medicare program and the overall drug channel. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Marketing 98

Marketing Pharmacy Drugs 98

Drug Channels

JUNE 20, 2023

Last Friday was the last day to submit comments on CMS's initial guidance on the drug price negotiation program. The IRA will alter many crucial aspects of the Medicare program and the overall drug channel. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Marketing 98

Marketing Pharmacy Drugs 98

Drug Channels

MAY 9, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. FYI, Managed Healthcare Executive (accurately) described my presentation as " mixing jokes with data and PowerPoint slides." Yes, that sounds about right.

Specialty Pharmacies 98

Specialty Pharmacies Marketing Pharmacy Drugs 98

Drug Channels

JANUARY 4, 2024

Paula and I have some exciting news to share with you: Drug Channels Institute is joining the HMP Global family! HMP is a leading omnichannel healthcare education, events, and market insights company. Please enjoy our special video message to the Drug Channels community: Click here if you can’t see the video.

Drugs 97

Drugs Marketing 97

Drug Channels

MARCH 8, 2022

Next week, Drug Channels Institute will release our 2022 Economic Report on U.S. It’s the 13th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

JULY 12, 2022

Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations —more than half of the entire U.S. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Pharmacy 98

Pharmacy Marketing Hospitals Drugs 98

Drug Channels

JUNE 6, 2022

Time for an update to the Drug Channels Institute (DCI) annual analysis of pharmacist salaries and employment. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Expect further declines as the shakeout continues.

Pharmacy 98

Pharmacy Hospitals Marketing Drugs 98

Drug Channels

MARCH 8, 2023

Next week, Drug Channels Institute will release our 2023 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. How will GoodRx and Mark Cuban Cost Plus Drug Company affect the pharmacy industry? Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmacy 98

Pharmacy Specialty Pharmacies Marketing Drugs 98

Drug Channels

APRIL 4, 2023

Time for Drug Channels Institute’s annual update on the gross-to-net bubble —the ever-growing dollar gap between sales at brand-name drugs' list prices and their sales at net prices after rebates and other reductions. We estimate that the gross-to-net bubble reached $223 billion for patent-protected brand-name drugs in 2022.

Marketing 75

Marketing Pharmacy Drugs 75

Drug Channels

JUNE 21, 2023

Time for Drug Channels Institute’s annual update on the gross-to-net bubble —the ever-growing dollar gap between sales at brand-name drugs' list prices and their sales at net prices after rebates and other reductions. We estimate that the gross-to-net bubble reached $223 billion for patent-protected brand-name drugs in 2022.

Marketing 75

Marketing Pharmacy Drugs 75

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Drug Channels

OCTOBER 6, 2020

The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. What’s more, manufacturers of reference products are cutting drug prices to defend their market shares.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

AUGUST 16, 2024

Today’s guest post comes from Benjamin Hinton II, Senior Market Access Solutions Analyst at MMIT. Click here to learn more about MMIT’s Custom Market Research offering for biosimilar manufacturers. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

Biosimilars 52

Biosimilars Marketing Production Research 52

Drug Channels

OCTOBER 24, 2023

For 2024: 94% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. 51% of Medicare Advantage prescription drug (MA-PD) plans will have a preferred network. The 2024 data provide early evidence of a shrinking PDP market. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmacy 52

Pharmacy Independent Pharmacies Marketing Drugs 52

Drug Channels

DECEMBER 17, 2020

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021. Drug pricing perceptions always seem to lag reality. The biosimilar market is finally beginning to fulfill its promise. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

SEPTEMBER 24, 2021

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. That means it’s time to update Drug Channels Institute’s (DCI) annual analysis of pharmacist salaries and employment. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc.

Hospitals 90

Hospitals Marketing Drugs Pharmacy 90

Drug Channels

JULY 9, 2024

As you will see below, CMS projects that outpatient prescription drugs dispensed by retail and mail pharmacies will remain a small share of total U.S. Nonetheless, taxpayers—primarily via Medicare and Medicaid—will continue to dominate the employer-sponsored insurance market. healthcare spending. healthcare spending.

Government 52

Government Specialty Pharmacies Pharmacy Drugs 52

Drug Channels

JULY 11, 2023

Looks like pharmacy and PBM profiteering within the 340B Drug Pricing Program will never go out of style. Drug Channels Institute’s (DCI) latest analysis reveals that more than 33,000 pharmacy locations —more than half of the entire U.S. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmacy 74

Pharmacy Marketing Hospitals Drugs 74

Drug Channels

OCTOBER 28, 2021

Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. To learn more about technology and access to specialty medications, read the CoverMyMeds Medication Access Report: Complex Care & Specialty Edition.

Marketing 75

Marketing Drugs 75

Drug Channels

MAY 22, 2024

In my recent Drug Channel Implications of the Inflation Reduction Act video webinar, I explained the intended and unintended consequences of the Inflation Reduction Act of 2022 (IRA) for the commercial market and drug channel participants. Curious about the IRA will disrupt the 340B market?

Drugs 52

Drugs Government Marketing Production 52

Drug Channels

MAY 9, 2024

To learn more about navigating the complexities of market access, contact MMIT and its sister company, The Dedham Group. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. They discuss five ways manufacturers can prevent these barriers from affecting patients. All rights reserved.

Therapies 98

Therapies Marketing Drugs 98

Drug Channels

JUNE 24, 2024

We have secured four outstanding fireside chat participants for our inaugural Drug Channels Leadership Forum , which will be held next March in Miami. Our fireside chats will illuminate crucial issues and key strategic concerns affecting the prescription drug market and the entire U.S. Good news, everyone! healthcare system.

Drugs 52

Drugs Marketing 52

Drug Channels

NOVEMBER 28, 2023

In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than one Pharmacists sing the retail pharmacy shakeout blues Plus, two Philly legends meet at a cardiology conference! d/b/a Drug Channels Institute.

Pharmacy 97

Pharmacy Drugs Marketing 97

Drug Channels

AUGUST 8, 2023

on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. Click here to read the Drug Channels Institute letter to Senators Thune, Stabenow, Moore Capito, Baldwin, Moran, and Cardin. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. I shared my $0.02

Pharmacy 96

Pharmacy Hospitals Drugs Pharmaceuticals 96

Drug Channels

AUGUST 6, 2024

I then document how five multi-billion-dollar, for-profit, publicly traded pharmacy chains and pharmacy benefit managers (PBMs)—Cigna (via Express Scripts), CVS Health, UnitedHealth Group (via OptumRx), and Walgreens, Walmart—continue to dominate the 340B contract pharmacy market. Click here if you can’t see the video below.

Pharmacy 52

Pharmacy Hospitals Marketing Drugs 52

Drug Channels

MAY 29, 2024

Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Summer unofficially began over the weekend. All rights reserved.

Biosimilars 52

Biosimilars Drugs Marketing 52

Drug Channels

AUGUST 9, 2024

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Chris reviews recent developments for the Inflation Reduction Act of 2022 (IRA). Read on for Chris’s insights. All rights reserved.

Marketing 52

Marketing Drugs 52

Drug Channels

MAY 2, 2024

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Chris explains how the Inflation Reduction Act of 2022 (IRA) will impact hub, patient assistance programs (PAP), and affordability programs.

Marketing 98

Marketing Drugs 98

Drug Channels

AUGUST 2, 2024

Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Read on for Stacey’s insights. All rights reserved. This Feed is for personal non-commercial use only.

Science 52

Science Marketing Drugs 52

Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98